PDS Biotechnology (NASDAQ:PDSB) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

PDSB has been the topic of several other research reports. Alliance Global Partners raised PDS Biotechnology to a strong-buy rating in a report on Wednesday, August 21st. B. Riley dropped their price objective on PDS Biotechnology from $11.00 to $9.00 and set a buy rating on the stock in a report on Wednesday, June 12th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $14.25.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock opened at $3.71 on Wednesday. The business has a 50-day simple moving average of $3.24 and a 200-day simple moving average of $3.35. The company has a market cap of $136.08 million, a PE ratio of -2.73 and a beta of 1.88. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter in the previous year, the company earned ($0.37) earnings per share. On average, equities research analysts forecast that PDS Biotechnology will post -1.3 EPS for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after purchasing an additional 82,135 shares in the last quarter. Blair William & Co. IL grew its stake in PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after buying an additional 81,743 shares during the last quarter. Inspirion Wealth Advisors LLC increased its position in PDS Biotechnology by 5.5% during the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock worth $1,406,000 after buying an additional 18,383 shares during the period. Tempus Wealth Planning LLC purchased a new stake in PDS Biotechnology in the second quarter valued at approximately $55,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $115,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.